Atisama Therapeutics said its lead candidate RB042 has advanced into multiple ascending dose cohorts in a…
Healthcare Innovation
MaxCyte Q1 2026 Earnings Call Transcript Highlights Commercial Platform Execution and Investor Focus
MaxCyte’s first-quarter 2026 earnings call provided a routine but important update on the cell-engineering company’s investor…